Previous 10 | Next 10 |
German clinical-stage biopharma InflaRx ( NASDAQ: IFRX ) on Thursday said it had submitted an emergency use approval request to the U.S. FDA for its monoclonal antibody vilobelimab to treat critically ill COVID-19 patients. The company also said it was granted a fast track...
Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory Medicine Request for EUA follows encouraging inte...
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences. H.C. Wainwright 24 ...
The Lancet Respiratory Medicine , a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in invasively mechanically ventilated, critically ill COVID-19 patients In-depth statist...
Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDA Plans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients announced Grant income of €14.4 million realized during the second quar...
GeoVax Labs ( GOVX ) +57% . Mobile Global Esports (MGAM) +45% . Celyad Oncology ( CYAD ) +40% as FDA lifts hold on colorectal cancer trial of CYAD-101/Keytruda. Virax Biolabs Group ( VRAX ) +38% . Aethlon Medical ( AEMD ) +35...
If you’re an active trader or looking for stock market news today, this is probably the one-millionth headline you’ve read with the phrase “Recession Begins” in the title. Apologies for that, but it’s true; we’re officially in a technical recession....
InvestorPlace - Stock Market News, Stock Advice & Trading Tips InflaRx (NASDAQ: IFRX ), a maker of anti-inflammatory therapeutics, is up 40% today after announcing it’s pursuing emergency-use authorization from the U.S. Food and Drug Administration for its Covid-19 treat...
Gainers: GeoVax Labs ( GOVX ) +42% . InflaRx ( IFRX ) +37% . Sunshine Biopharma ( SBFM ) +35% . Nutriband ( NTRB ) +29% . Talaris Therapeutics ( TALS ) +24% . Chimerix ( CMRX ) +20% . Liberty TripAdvisor Holdings ...
Gainers: Sunshine Biopharma ( SBFM ) +26% . InflaRx IFRX +14% . Talaris Therapeutics ( TALS ) +8% . Nutriband ( NTRB ) +7% . Biodesix ( BDSX ) +5% . Losers: Revelation Biosciences REVB -52% . Virax Biolabs VR...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...